research use only
Cat.No.S7321
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Other Phospholipase (e.g. PLA) Inhibitors | Varespladib (LY315920) Darapladib (SB-480848) GW4869 U-73122 Tanshinone I Quinacrine 2HCl (E/Z)-Polydatin Melittin Trigonelline CAY10593 (VU0155069) |
|
In vitro |
DMSO
: 45 mg/mL
(106.76 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 421.47 | Formula | C23H24FN5O2 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 939055-18-2 | -- | Storage of Stock Solutions |
|
|
| Synonyms | 5-Fluoro-2-indolyl deschlorohalopemide | Smiles | C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCNC(=O)C4=CC5=C(N4)C=CC(=C5)F | ||
| Targets/IC50/Ki |
PLD2
(Cell-free assay) 20 nM
PLD1
(Cell-free assay) 25 nM
|
|---|---|
| In vitro |
FIPI inhibits both PLD1 and PLD2 in a dose-dependent manner, with 50% loss of activity observed at approximately 25 nM. This compound efficiently crosses cell membranes and inhibits PLD1 and PLD2 action on their endogenous substrate in the cytoplasmic environment. |
| In vivo |
Mice that receives FIPI at a dose of 3 mg/kg displayes reduced occlusive thrombus formation upon chemical injury of carotid arteries or mesenterial arterioles. Similarly, this compound-treated mice has smaller infarct sizes and significantly better motor and neurological function 24 hours after transient middle cerebral artery occlusion. This protective effect is not associated with major intracerebral hemorrhage or prolonged tail bleeding times. |
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.